02.06.2025 10:31:16

Theravance Biopharma To Sell Remaining Interest In Trelegy Ellipta To GSK For $225 Mln, Stock Up

(RTTNews) - Theravance Biopharma, Inc. (TBPH), Monday announced an agreement to sell remaining interest in net sales of Trelegy Ellipta, a chronic obstructive pulmonary disease or asthma treatment, to GSK (GSK) for $225 million in cash.

This move comes as a result of the ongoing efforts of the Strategic Review Committee of the Board of Directors, which focuses on disciplined capital allocation and returning excess cash to shareholders.

Notably, the company will continue to retain its right to receive upto $150 million in remaining Trelegy sales related milestones in 2025 and 2026 from Royalty Pharma.

The company further assured that its financial outlook for 2025 remains unchanged.

In the pre-market hours, TBPH is trading at $10.52, up 14.85 percent on the Nasdaq.

Analysen zu Theravance Biopharma Inc When Issuedmehr Analysen

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Theravance Biopharma Inc When Issued 9,35 0,00% Theravance Biopharma Inc When Issued
pagehit